filings.toolsItem 5. Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
8K characters. Original on sec.gov · Markdown
Item 5. Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
| (a) | Market Information: The principal market on which the Company’s common stock is traded is the New York Stock Exchange (“NYSE”). |
The following table sets forth the high and low sales prices for our common stock as reported on NYSE for each quarterly period of the two most recently completed fiscal years:
| 2017 | 2016 | ||||||||||||
| High | Low | High | Low | ||||||||||
| First quarter | $ | 188.43 | $ | 154.33 | $ | 243.61 | $ | 219.51 | |||||
| Second quarter | $ | 199.43 | $ | 163.57 | $ | 236.86 | $ | 160.10 | |||||
| Third quarter | $ | 166.78 | $ | 114.53 | $ | 202.20 | $ | 169.00 | |||||
| Fourth quarter | $ | 153.07 | $ | 134.17 | $ | 196.84 | $ | 148.29 |
| (b) | Holders: The number of record holders of the Company’s common stock at March 31, 2017 was approximately 5,974. |
| (c) | Dividends: In July 2015, the Company’s quarterly dividend was raised from $0.24 to $0.28 per common share for dividends declared after such date, until further action by the Company’s Board of Directors (the “Board”). The Company declared regular cash dividends of $1.12 and $1.08 per share in the years ended March 31, 2017 and 2016. |
The Company anticipates that it will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company’s future earnings, financial condition, capital requirements and other factors.
| (d) | Securities Authorized for Issuance under Equity Compensation Plans: Information relating to this item is provided under Part III, Item 12, to this Annual Report on Form 10-K. |
| (e) | Share Repurchase Plans: Stock repurchases may be made from time to time in open market transactions, privately negotiated transactions, through accelerated share repurchase (“ASR”) programs, or by any combination of such methods. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including our stock price, corporate and regulatory requirements, restrictions under our debt obligations and other market and economic conditions. |
During the last three years, our share repurchases were transacted through both open market transactions and ASR programs with third-party financial institutions.
In May and October 2015, the Board authorized the repurchase of up to $500 million and $2 billion of the Company’s common stock.
In 2016, we repurchased 4.5 million of the Company’s shares for $854 million through open market transactions at an average price per share of $192.27. In February 2016, we entered into an ASR program with a third-party financial institution to repurchase $650 million of the Company’s common stock. This ASR program was completed during the 2016 fourth quarter and we repurchased 4.2 million shares at an average price per share of $154.04. During 2016, we completed the May 2015 share repurchase authorization. At March 31, 2016, $1.0 billion remained available for future authorized repurchases of the Company’s common stock under the October 2015 authorization.
In October 2016, the Board authorized the repurchase of up to $4.0 billion of the Company’s common stock.
In 2017, we repurchased 14.1 million of the Company’s shares for $2 billion through open market transactions at an average price per share of $140.96. In March 2017, we entered into an ASR program with a third-party financial institution to repurchase $250 million of the Company’s common stock. As of March 31, 2017, we had received 1.4 million shares under this program. This ASR program was completed in April 2017 and we received 0.3 million additional shares. The total number of shares repurchased under this ASR program was 1.7 million shares at an average price per share of $143.19. During 2017, we completed the October 2015 share repurchase authorization. The total authorization outstanding for repurchases of the Company’s common stock was $2.7 billion at March 31, 2017.
McKESSON CORPORATION
In 2016, we retired 115.5 million or $7.8 billion of the Company’s treasury shares previously repurchased. Under the applicable state law, these shares resume the status of authorized and unissued shares upon retirement. In accordance with our accounting policy, we allocate any excess of share repurchase price over par value between additional paid-in capital and retained earnings. Accordingly, our retained earnings and additional paid-in capital were reduced by $6.4 billion and $1.5 billion during 2016.
The following table provides information on the Company’s share repurchases during the fourth quarter of 2017:
| Share Repurchases (1) | |||||||||||||
| (In millions, except price per share) | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs | |||||||||
| January 1, 2017 - January 31, 2017 | — | $ | — | — | $ | — | |||||||
| February 1, 2017 - February 29, 2017 | — | — | — | — | |||||||||
| March 1, 2017 - March 31, 2017 | 1.4 | 143.19 | 1.4 | 2,746 | |||||||||
| Total | 1.4 | 1.4 | $ | 2,746 |
| (1) | This table does not include shares tendered to satisfy the exercise price in connection with cashless exercises of employee stock options or shares tendered to satisfy tax-withholding obligations in connection with employee equity awards. |
McKESSON CORPORATION
| (f) | Stock Price Performance Graph*: The following graph compares the cumulative total stockholder return on the Company’s common stock for the periods indicated with the Standard & Poor’s 500 Index and the S&P 500 Health Care Index. The S&P 500 Health Care Index was selected as a comparator because it is generally available to investors and broadly used by other companies in the same industry. |
| March 31, | |||||||||||||||||||||||
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | ||||||||||||||||||
| McKesson Corporation | $ | 100.00 | $ | 124.07 | $ | 204.26 | $ | 262.91 | $ | 183.82 | $ | 174.50 | |||||||||||
| S&P 500 Index | $ | 100.00 | $ | 113.96 | $ | 138.87 | $ | 156.55 | $ | 159.34 | $ | 186.71 | |||||||||||
| S&P 500 Health Care Index | $ | 100.00 | $ | 125.19 | $ | 161.79 | $ | 204.17 | $ | 193.59 | $ | 216.03 |
- Assumes $100 invested in McKesson Common Stock and in each index on March 31, 2012 and that all dividends are reinvested.
McKESSON CORPORATION
Previous: Item 4. Mine Safety Disclosures. · Next: Item 6. Selected Financial Data.